 XOMA has built a large portfolio of drug royalties, over 65, with the potential to build a biotechnology business with high upside but limited and diversified downside protection. This royalty aggregator model has the potential to build a substantial balance sheet for XOMA, which will lower the companys cost-of-capital and enable it to build an even larger portfolio. 